Vivacta, a medical diagnostics company, has closed a GBP4m financing round.
The current shareholders, HBM BioVentures, IDInvest Partners (formerly AGF Private Equity), Spark Ventures and Viking, all participated in the round.
Vivacta’s piezofilm technology platform enables the development of a new generation of near-patient diagnostic products achieving high sensitivity and wide dynamic range, equivalent to laboratory testing. The test uses whole blood samples and requires only a finger prick sample, providing actionable results within ten minutes.
Vivacta has developed a diagnostic test for thyroid stimulating hormone, one of the most widely prescribed laboratory tests and the industry gold standard for immunoassays by which major diagnostic companies measure the performance of competing platforms.
Vivacta is also developing a multiple analyte cardiovascular diagnostic test for use in the emergency room and acute care settings.
Tim Carter, chief executive officer of Vivacta and co-inventor of the piezofilm platform technology, says: “Our technology has the potential to revolutionise point of care diagnosis. This fundraising enables us to continue to maximise the potential of our platform and demonstrates the commitment of our investors in the company.”
